
Canton Biologics
Guangzhou, China cantonbio.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
Canton Biologics is a biologics CDMO focused on CMC development and manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, and recombinant proteins. It serves global biopharmaceutical clients from sites in Guangzhou, Foshan, Berlin, and Hong Kong, with services spanning R&D through commercial manufacturing and quality support.
Services
Antibody Discovery
Supports target validation, antigen design and production, animal immunization, library generation, candidate screening, and antibody engineering.
Developability Assessment
Assesses properties such as specificity, binding, stability, aggregation, and other developability characteristics for antibody candidates.
Cell Line Development
Provides cell line construction and development services for biologics expression systems.
Cell line development
High-Efficiency Expression Vector
Offers expression vector technologies including Canvector® and IgMax® for protein production.
Cell line development
Process Analytical Methods
Develops analytical methods to support biologics process development and characterization.
Microbial CGT
Provides development and manufacturing services for microbial and CGT-related programs.
Tech Transfer
Supports transfer of processes into development, pilot, and manufacturing settings.
Drug Substance
Provides drug substance process development and manufacturing support.
CDMO: development & manufacturing
9 more services
- Drug Product
- Process Characterization
- Process Validation
- Quality Control
- Quality Assurance
- Regulatory Affairs
- Project Management
- IP Management
- Animal Health
- Turnaround
- 4 weeks to 26 months
- What to send
- AAV samples
- Cell products
- Live microecological products
- Utility system samples including water, environment, and gases
- Incoming materials including media, reagents, excipients, and primary packaging materials
Capabilities
- Assays and studies
- CHO
- Antibodies
- Process development
- Bispecifics
- Analytical development
- E. coli expression
17 more
- Flow cytometry
- HEK293
- Target validation
- Binding epitope analysis
- Affinity analysis
- Cell cytotoxicity/proliferation
- Immune cell activation
- Cell differentiation/polarization
- ADCC
- ADCP
- CDC
- Cytokine release
- Antibody internalization
- Purity analysis
- Stability analysis
- Analytical method transfer
- Method validation
- Scale and capacity
- Pilot-scale production (50/200L)
- Commercial-scale production (2000L)
- Five 2,000 L Cytiva single-use bioreactors
- Up to 10,000 L total culture volume per batch
- Kunlun mammalian GMP manufacturing site (12,000㎡)
- Guangzhou Penglai microbial R&D and GMP manufacturing site (14,000㎡)
- Therapeutic areas
- Biologics
- Animal health
Instruments and platforms
- FACS
- Circular dichroism
- Advanced MS-MS
- Single-use bioreactors
- Cytiva single-use bioreactors
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Viral vector
- Cell therapy
- Recombinant protein
- Species and models
- CHO-K1
- CHO-DG44
- CHO-DXB11
- NS0
- SP2/0
- HEK293(T)
- E. coli
- Human myeloid leukemia cell line
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2016
- Address
- 19 Nanxiang Third Road, Huangpu District, Guangzhou Hong Kong SAR Office
- Sites
- Berlin, Germany
- Foshan, China
- Hong Kong, China
- Serves
- Global